The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis.

The adverse events of toripalimab in nasopharyngeal carcinoma based on FAERS database and bibliometric analysis.

Show other versions (1)

<h4>Background</h4>Toripalimab, a monoclonal antibody designed to target PD-1, has recently received approval from the U.S. Food and Drug Administration (FDA) for use as a first-line treatment in adults diagnosed with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC...

Full description

Saved in:
Bibliographic Details
Main Authors: Qian Guo, Dong Dong, Zihan Dang, Shuman Huang, Xinjie Qiao, Baiquan Zhang, Yulin Zhao
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0326216
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items